Respiratory tract infections were the most common infection observed in patients with SID treated with different biologics and immunomodulatory therapies, including tumor necrosis factor-α inhibitors, interleukin-12/interleukin-23 inhibitors, anti-T-lymphocyte therapies, and anti-B-lymphocyte therapies [19]. Here, IL37 is linked to infection.